Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Antibodies, Monoclonal; Ipilimumab; Sunitinib; Tremelimumab

Criteria

Inclusion Criteria:

• Histologically proven renal cell carcinoma with metastases

• Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1

Exclusion Criteria:

• Prior treatment with more than one systemic therapy for metastatic renal cell carcinoma

• History of or known brain metastases, spinal cord compression or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening Computed Axial Tomography (CT) or Magnetic Resonance Imaging (MRI) scan